U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT07590908) titled 'CARA-VT: a Dosimetric in Silico Study' on Nov. 14, 2025.
Brief Summary: Ventricular tachycardia (VT) is a potentially deadly condition, common in patients with structural heart disease or dilated cardiomyopathy. VTpatients are currently treated with anti-arrhythmic drugs, implanted cardioverter defibrillators or invasive catheter ablation (CA) but the overall success rate of this techniqueis still suboptimal.
One of the main reasons is an anatomically inaccessible location of VT's origin (within the mid-wall of the myocardium, on the epicardial site or adjacent to critical structures). Moreover, repeated invasive ablation, technical...